Previous studies showed that the pathological grade of NASH and occurrence of HCC was suppressed by treatment with SGLT2 inhibitors in some morbidly obese rodent models44,45, suggesting that inhibition of SGLT may be beneficial for the suppression of NASH/NCC associated with severe insulin resistance. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.